The Interleukin 18 pipeline drugs market research report outlays comprehensive information on the Interleukin 18 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Interleukin 18 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Dermatology, Gastrointestinal, and Infectious Disease which include the indications Osteosarcoma, Glioblastoma Multiforme (GBM), Atopic Dermatitis (Atopic Eczema), Hidradenitis Suppurativa, Ulcerative Colitis, Crohn’s Disease (Regional Enteritis), Coronavirus Disease 2019 (COVID-19), and Coronavirus Disease 2019 (COVID-19) Pneumonia. It also reviews key players involved in Interleukin 18 targeted therapeutics development with respective active and dormant or discontinued products.
The Interleukin 18 pipeline targets constitutes close to 13 molecules. Out of which, approximately 11 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 2, 4, 2, 2, and 1 respectively. Similarly, the universities portfolio in Phase I comprises 2 molecule.
Interleukin 18 overview
Interleukin 18 (IL18) is a proinflammatory cytokine of the IL-1 family that is found as a precursor within the cytoplasm of a variety of cells including macrophages and keratinocytes. It is involved in epithelial barrier repair, polarized T-helper 1 (Th1) cell and natural killer (NK) cell immune responses. Upon binding to IL18R1 and IL18RAP, it forms a signaling ternary complex that activates NF-kappa-B, triggering synthesis of inflammatory mediators.
For a complete picture of Interleukin 18’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
